Effects of canagliflozin combined with losenatide on islet function,YKL-40,PPAR-γ in type 2 diabetes patients with insulin resistance
Aim To study the efficacy of canagliflozin combined with losenatide in the treatment of insulin resistance in type 2 diabetes patients,as well as the effect on pancreatic islet function,serum YKL-40,peroxisome proliferator activated receptor γ(PPARγ).Methods 98 patients with type 2 diabetes were randomly divided into a control group(treated with losenatide)and a combination group(treated with canagliflozin and losenatide).The clinical efficacy,islet function,serum YKL-40 and PPARγ lev-els,blood glucose indicators,and incidence of adverse reactions of the two groups were compared.Results The total effective rate of the combination group was higher than that of the control group(P＜0.05).There was no significant difference in the total in-cidence of adverse reactions between the two groups(P＞0.05).Compared with before treatment,the area under the insulin curve,pancreatic β cell function index,PPARγ in both groups after treatment were increased,where as insulin resistance index,YKL-40,fasting blood glucose,2 hour postprandial blood glucose,glycated hemoglobin,and body mass index were increased,and the combined group showed more significant changes(P＜0.05).Conclusion Canagliflozin combined with losenatide can effectively improve the islet function of insulin resistance patients with type 2 diabetes mellitus,and significantly improve YKL-40 and PPARγ Level,which is worth of recommending.
canagliflozinlosenatidetype 2 diabetesYKL-40PPARγislet function
万方数据
维普
